For Healthcare Professionals
The first and only FDA-approved therapy for the treatment of patients with Multicentric Castleman’s Disease (MCD) who are human immunodeficiency virus (HIV) negative and human herpesvirus-8 (HHV-8) negative.
Limitation of use: SYLVANT® was not studied in patients with MCD who are HIV positive or HHV-8 positive because SYLVANT® did not bind to virally produced IL-6 in a nonclinical study1.
- SYLVANT® [package insert]. Hertfordshire, UK: EUSA Pharma UK Ltd; June 2019.